Inherited thrombophilia: Key points for genetic counseling

Journal of Genetic Counseling

Volumn 16, Issue 3, 2007, Pages 261-277

  Varga, Elizabeth ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Factor V Leiden; Genetic counseling; Prothrombin; Recurrent pregnancy loss; Risk assessment; Thrombophilia; Venous thromboembolism

Indexed keywords

ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; FIBRINOLYTIC AGENT; HEPARIN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; WARFARIN;

3' UNTRANSLATED REGION; ANAMNESIS; ANTICOAGULANT THERAPY; ANTITHROMBIN DEFICIENCY; ANTITHROMBIN III DEFICIENCY; ARTERY THROMBOSIS; CANCER; DATA ANALYSIS; DIABETES MELLITUS; EMPLOYMENT DISCRIMINATION; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FAMILY; FAMILY HISTORY; FOLLOW UP; FULMINATING PURPURA; GENE MUTATION; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC RISK; HEALTH INSURANCE; HEART INFARCTION; HIGH RISK PATIENT; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; HYPERTENSION; INFERTILITY THERAPY; LIFESTYLE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MEDICAL PERSONNEL; MUTATIONAL ANALYSIS; OBESITY; ORAL CONTRACEPTION; PATIENT EDUCATION; POSTTHROMBOSIS SYNDROME; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PUBLIC HEALTH; RECURRENT ABORTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SOCIAL PSYCHOLOGY; SOCIAL SUPPORT; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; THROMBOSIS; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

ABORTION, HABITUAL; ANTITHROMBIN III DEFICIENCY; FACTOR V; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HOMOCYSTEINE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMORPHISM, GENETIC; PREGNANCY; PROTHROMBIN; REFERRAL AND CONSULTATION; RISK ASSESSMENT; THROMBOEMBOLISM; THROMBOPHILIA;

EID: 34249946741     PISSN: 10597700     EISSN: 15733599     Source Type: Journal    
DOI: 10.1007/s10897-006-9069-9     Document Type: Review

References (116)

1. ACOG practice bulletin: Management of recurrent pregnancy loss. Number 24, February 2001. (Replaces Technical Bulletin Number 212, September 1995). American College of Obstetricians and Gynecologists. (2002). Int J Gynaecol Obstet, 78(2), 179-190.
2. ACOG Practice Bulletin #68: Antiphospholipid syndrome. (2005). Obstet Gynecol, 106(5 Pt 1), 1113-1121.
3. Agorastos, T., Karavida A., Lambropoulos A., Constantinidis, T., Tzitzimikas S., & Chrisafi S., et al. (2002). Factor V Leiden and prothrombin G20210A mutations in pregnancies with adverse outcome. J Matern Fetal Neonatal Med, 12(4), 267-273.
4. Andersen, B. S., & Olsen, J. (1998). Oral contraception and factor V Leiden mutation in relation to localization of deep vein thrombosis. Thromb Res, 90(4), 191-194.
5. Anderson, F. A., Jr., Wheeler, H. B., Goldberg, R. J., Hosmer, D. W., Forcier, A., & Patwardhan, N. A. (1991). Physician practices in the prevention of venous thromboembolism. Ann Intern Med, 115(8), 591-595.
6. Balasch, J., Reverter, J. C., Fabregues, F., Tassies, D., Rafel, M., Creus, M., & Vanrell, J. A. (1997). First-trimester repeated abortion is not associated with activated protein C resistance. Hum Reprod, 12(5), 1094-1097.
7. Bank, I., Scavenius, M. P., Buller, H. R., & Middeldorp, S. (2004). Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res, 113(1), 7-12.
8. Barbour, L. A. (2001). ACOG practice bulletin. Thrombembolism in pregnancy. Int J Gynaecol Obstet, 75(2), 203-212.
9. Bates, S. M., Greer, I. A., Hirsh, J., & Ginsberg, J. S. (2004). Use of antithrombotic agents during pregnancy, the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 126(3 Suppl), 627S-644S.
10. Bauer, K. A. (2001). The thrombophilias: well-defined risk factors with uncertain therapeutic implications. Ann Intern Med, 135(5), 367-373.
11. Beauchamp, N. J., Dykes, A. C., Parikh, N., Campbell Tait, R., & Daly, M. E. (2004). The prevalence of, and molecular defects underlying, inherited protein S deficiency in the general population. Br J Haematol, 125(5), 647-654.
12. Bertina, R. M., Koeleman, B. P., Koster, T., Rosendaal, F. R., Dirven, R. J., de Ronde, H., Van Der Velden, P. A., & Reitsma, P. H. (1994). Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature, 369(6475), 64-67.
13. Bonaa, K., Njolstad I., Ueland, P., Schirmer, H., Tverdal, A., Steigen, T., et al. (2006). Homocysteine lowering and cardiovascular events after acute myocardial infarction. NEJM, (354), 1578-1588.
14. Bos, M. J., Heijer, M., Willems, H., Blom H., Gerrits W., Cattaneo M., et al. (2004). Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A first randomized, placebo-controlled, double-blind trial. Blood, 104, 142a.
15. Botto, L. D., & Yang, Q. (2000). 5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGE review. Am J Epidemiol, 151(9), 862-877.
16. Brenner, B. R., Nowak-Gottl, U., Kosch, A., Manco-Johnson, M., & Laposata, M. (2002). Diagnostic studies for thrombophilia in women on hormonal therapy and during pregnancy, and in children. Arch Pathol Lab Med, 126(11), 1296-1303.
17. Brenner, B., Horrman, R., Carp, H., Dulitsky, M., Younis, J. (2005). Efficacy and safety of two doses of enoxaparin in women with thrombophilia and recurrent pregnancy losses: the LIVE-ENOX study. J Thromb Haemost, 3, 227-229.
18. Brill-Edwards, P., Ginsberg, J. S., Gent, M., Hirsh, J., Burrows, R., Kearon, C., Geerts, W., Kovacs, M., Weitz, J. I., Robinson, K. S., Whittom, R., & Couture, G. (2000). Safety of withholding heparin in pregnant women with a history of venous thromboembolism. Recurrence of clot in this pregnancy study group. N Engl J Med, 343(20), 1439-1444.
19. Caprini, J. A., Glase, C. J., Anderson, C. B., & Hathaway, K. (2004). Laboratory markers in the diagnosis of venous thromboembolism. Circulation, 109(12 Suppl 1), I4-I8.
20. College of American Pathologists Consensus Conference XXXVI: Diagnostic Issues in Thrombophilia. (2002). Arch Pathol Lab Med, 126(11), 1277-1433.
21. Copel, J. O. T. (2002). Deciphering the role of thrombophilias in recurrent miscarriage: impact on screening and treatment. Contemporary OB/GYN, 6, 122-132.
22. Cosmi, B., Legnani, C., Bernardi, F., Coccheri, S., & Palareti, G. (2003). Role of family history in identifying women with thrombophilia and higher risk of venous thromboembolism during oral contraception. Arch Intern Med, 163(9), 1105-1109.
23. Cushman, M. (2005). Inhertied risk factors for venous thrombosis. Hematology (Am Soc Hematol Educ Program) 452-457.
24. De Stefano, V., Casorelli, I., Rossi, E., Zappacosta, B., & Leone, G. (2000). Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Semin Thromb Hemost, 26(3), 305-311.
25. De Stefano, V., Martinelli, I., Mannucci, P. M., Paciaroni, K., Chiusolo, P., Casorelli, I., Rossi, E., & Leone, G. (1999). The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med, 341(11), 801-806.
26. den Heijer, M., & Keijzer, M. B. (2001). Hyperhomocysteinemia as a risk factor for venous thrombosis. Clin Chem Lab Med, 39(8), 710-713.
27. Dizon-Townson, D., Miller, C., Sibai, B., Spong, C. Y., Thom, E., Wendel, G., et al. (2005). The relationship of the factor V Leiden mutation and pregnancy outcomes for mother and fetus. Obstet Gynecol, 106(3), 517-524.
28. Egeberg, O. (1965). Inherited Antithrombin Deficiency Causing Thrombophilia. Thromb Diath Haemorrh, 13, 516-530.
29. Eichinger, S., Pabinger, I., Stumpflen, A., Hirschl, M., Bialonczyk, C., Schneider, B., et al. (1997). The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost, 77(4), 624-628.
30. Eichinger, S., & Kyrle, P. A. (2004). Prevention of deep vein thrombosis in orthopedic surgery. Eur J Med Res, 30;9(3), 112-118.
31. Esfahani, S. T., Cogger, E. A., & Caudill, M. A. (2003). Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J Am Diet Assoc, 103(2), 200-207.
32. FDA Updates Labeling for Ortho Evra Contraceptive Patch. FDA News, November 10, 2005, http://www.fda.gov/bbs/topics/news/2005/NEW01262.html. Accessed September 15, 2006.
33. Franco, R. F., Santos, S. E., Elion, J., Tavella, M. H., & Zago, M. A. (1998). Prevalence of the G20210A polymorphism in the 3′-untranslated region of the prothrombin gene in different human populations. Acta Haematol, 100(1), 9-12.
34. Frosst, P., Blom, H. J., Milos, R., Goyette, P., Sheppard, C. A., Matthews, R. G., et al. (1995). A candidate genetic risk factor for vascular disease: A common mutation in methylenetetrahydrofolate reductase. Nat Genet, 10(1), 111-113.
35. Ginsberg, J. S., Kowalchuk G., & Hirsh J. (1989). Heparin therapy during pregnancy. Risks to the fetus and the mother. Arch Intern Med, 149, 2233-2236.
36. Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, et al. (2004). Prevention of venous thromboembolism: The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest, 126(3 Suppl), 338S-400S.
37. Goldhaber, S., & Fanikos, J. (2004). Prevention of deep vein thrombosis and pulmonary embolism. Circulation, 110, e445-e447.
38. Gompel, A., Levy, D. P., & Conard, J. (2002). Ovarian hyperstimulation and thrombosis. Women's Issues Thrombosis and Haemostasis, London: Martin Dunitz pp. 143-150
39. Greaves, M., & Watson, H. G. (2003). Laboratory testing for prothrombotic states: Clinical utility. Curr Hematol Rep, 2(5), 429-434.
40. Greer, I. A. (2005). Venous thromboembolism and anticoagulant therapy in pregnancy. Gend Med, 2(Suppl A), S10-17.
41. Gris, J. C., Ripart-Neveu S., Maugard C., Tailland, M. L., Brun S., Courtieu, C., Biron C., et al. (1997). Respective evaluation of the prevalence of haemostasis abnormalities in unexplained primary early recurrent miscarriages. The Nimes Obstetricians and Haematologists (NOHA) Study. Thromb Haemost, 77(6), 1096-1103.
42. Gris, J. C., Mercier, E., Quere, I., Lavigne-Lissalde, G., Cochery-Nouvellon, E., Hoffet, M., et al. (2004). Low-molecular-weight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood, 103(10), 3695-3699.
43. Grody, W. W., Griffin, J. H., Taylor, A. K., Korf, B. R., & Heit, J. A. (2001). American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med, 3(2), 139-148.
44. Haas, S. (2001). Prevention of venous thromboembolism: Recommendations based on the international consensus and the american college of chest physicians sixth consensus conference on antithrombotic therapy. Clin Appl Thromb Hemost, 7(3), 171-177.
45. Heit, J. (2005). Estimated annual number of incident and recurrent, non-fatal and fatal venous thromboembolism (VTE) events in the US. Blood, 106, 267a.
46. Heit, J. A. (2006). The epidemiology of venous thromboembolism in the community: Implications for prevention and management. J Thromb Thrombolysis, 21(1), 23-29.
47. Heit, J. A., O'Fallon, W. M., Petterson, T. M., Lohse, C. M., Silverstein, M. D., Mohr, D. 3rd et al., (2002). Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: A population-based study. Arch Intern Med, 162(11), 1245-1248.
48. Hellgren, M., Svensson, P. J., & Dahlback, B. (1995). Resistance to activated protein C as a basis for venous thromboembolism associated with pregnancy and oral contraceptives. Am J Obstet Gynecol, 173(1), 210-213.
49. Hellmann, E. A., Leslie, N. D., & Moll, S. (2003). Knowledge and educational needs of individuals with the factor V Leiden mutation. J Thromb Haemost, 1(11), 2335-2339.
50. Hellmann, E., & Moll, S. (2004). Prothrombin 20210 mutation (Factor II Mutation). Circulation, 110, e15-e18.
51. Hirsch, D. R., Mikkola, K. M., Marks, P. W., Fox, E. A., Dorfman, D. M., Ewenstein, B. M., et al. (1996). Pulmonary embolism and deep venous thrombosis during pregnancy or oral contraceptive use: Prevalence of factor V Leiden. Am Heart J, 131(6), 1145-1148.
52. Hirsh, J., Piovella, F., & Pini, M. (1989). Congenital antithrombin III deficiency. Incidence and clinical features. Am J Med, 87(3B), 34S-38S.
53. James, A., Abel, D., & Brancazio, L. (2005). Anticoagulants in Pregnancy. Obstet Gynecol Survey, 61(1), 59-69.
54. Kamphuisen, P. W., & Rosendaal, F. R. (2004). Thrombophilia screening: A matter of debate. Neth J Med, 62(6), 180-187.
55. Kang, S. S., Zhou, J., Wong, P. W., Kowalisyn, J., & Strokosch, G. (1988). Intermediate homocysteinemia: A thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet, 43(4), 414-421.
56. Kearon, C. (1999). Initial treatment of venous thromboembolism. Thromb Haemost, 82(2), 887-891.
57. Klerk, M., Verhoef, P., Clarke, R., Blom, H. J., Kok, F. J., & Schouten, E. G. (2002). MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. Jama, 288(16), 2023-2031.
58. Koster, T., Rosendaal, F. R., de Ronde, H., Briet, E., Vandenbroucke, J. P., & Bertina, R. M. (1993). Venous thrombosis due to poor anticoagulant response to activated protein C, leiden thrombophilia study. Lancet, 342(8886-8887), 1503-1506.
59. Kottke-Marchant, K. (2002). Genetic polymorphisms associated with venous and arterial thrombosis: An overview. Arch Pathol Lab Med, 126(3), 295-304.
60. Kottke-Marchant, K., & Comp, P. (2002). Laboratory issues in diagnosing abnormalities of protein C, thrombomodulin, and endothelial cell protein C receptor. Arch Pathol Lab Med, 126(11), 1337-1348.
61. Kottke-Marchant, K., & Duncan, A. (2002). Antithrombin deficiency: issues in laboratory diagnosis. Arch Pathol Lab Med, 126(11), 1326-1336.
62. Kupferminc, M. J., Eldor, A., Steinman, N., Many, A., Bar-Am, A., Jaffa, A., et al. (1999). Increased frequency of genetic thrombophilia in women with complications of pregnancy. N Engl J Med, 340(1), 9-13.
63. Kupferminc, M. J., Fait, G., Many, A., Gordon, D., Eldor, A., & Lessing, J. B. (2000). Severe preeclampsia and high frequency of genetic thrombophilic mutations. Obstet Gynecol, 96(1), 45-49.
64. Laurino, M. Y., Bennett, R. L., Saraiya, D. S., Baumeister, L., Doyle, D. L., Leppig, K., et al. (2005). Genetic evaluation and counseling of couples with recurrent miscarriage: recommendations of the national society of genetic counselors. J Genet Couns, 14(3), 165-181.
65. Lensen, R. P., Bertina, R. M., de Ronde, H., Vandenbroucke, J. P., & Rosendaal, F. R. (2000). Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost, 83(6), 817-821.
66. Lewis, S. J., Ebrahim, S., & Davey Smith, G. (2005). Meta-analysis of MTHFR 677C-T polymorphism and coronary heart disease: does totality of evidence support causal role for homocysteine and preventive potential of folate? BMJ, 331(7524), 1053.
67. Lindmarker, P., Schulman, S., Sten-Linder, M., Wiman, B., Egberg, N., & Johnsson, H. (1999). The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC trial study group. duration of anticoagulation. Thromb Haemost, 81(5), 684-689.
68. Lockwood, C. J. (2002). Inherited thrombophilias in pregnant patients: detection and treatment paradigm. Obstet Gynecol, 99(2), 333-341.
69. Makris, M., Rosendaal, F. R., & Preston, F. E. (1997). Familial thrombophilia: genetic risk factors and management. J Intern Med Suppl, 740, 9-15.
70. Marlar, R. A., Montgomery, R. R., & Broekmans, A. W. (1989). Report on the diagnosis and treatment of homozygous protein C deficiency: Report of the working party on homozygous protein C deficiency of the ICTH-subcommittee on protein C and protein S. Thromb Haemost, 61(3), 529-531.
71. Martinelli, I. (2001). Risk factors in venous thromboembolism. Thromb Haemost, 86(1), 395-403.
72. Martinelli, I. (2003). Pros and cons of thrombophilia testing: pros. J Thromb Haemost, 1(3), 410-411.
73. Martinelli, I., Taioli, E., Bucciarelli, P., Akhavan, S., & Mannucci, P. M. (1999). Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol, 19(3), 700-703.
74. Measurement and use of total plasma homocysteine. American Society of Human Genetics/American College of Medical Genetics Test and Transfer Committee Working Group. (1998). Am J Hum Genet, 63(5), 1541-1543.
75. Middeldorp, S., Henkens, C. M., Koopman, M. M., van Pampus, E. C., Hamulyak, K., Van Der Meer, et al. (1998). The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med, 128(1), 15-20.
76. Miletich, J., Sherman, L., & Broze, G., Jr. (1987). Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med, 317(16), 991-996.
77. Misita, C., & Moll, S. (2005). Antiphospholipid antibodies. Circulation, 112, e39-e44.
78. Moll, S. (2006). Thrombophilias-practical implications and testing caveats. J Thromb Thrombolysis, 21(1), 7-15.
79. Nicolaides, A. N. (2005). Thrombophilia and venous thromboembolism. international consensus statement: Guidelines according to scientific evidence. Int Angiol, 24(1), 1-26.
80. Ornstein, D. L., & Cushman M. (2003). Factor V Leiden. Circulation 107, e94-e97.
81. Ozcan, T., & Copel, J. (2002). Deciphering the role of thrombophilias in recurrent miscarriage. Contemporary OB/GYN, 6, 122-132.
82. Poort, S. R., Rosendaal, F. R., Reitsma, P. H., & Bertina, R. M. (1996). A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood, 88(10), 3698-3703.
83. Press, R. D., Bauer, K. A., Kujovich, J. L., & Heit, J. A. (2002). Clinical utility of factor V leiden (R506Q) testing for the diagnosis and management of thromboembolic disorders. Arch Pathol Lab Med, 126(11), 1304-1318.
84. Ray, J. G., Shmorgun, D., & Chan, W. S. (2002). Common C677T polymorphism of the methylenetetrahydrofolate reductase gene and the risk of venous thromboembolism: meta-analysis of 31 studies. Pathophysiol Haemost Thromb, 32(2), 51-58.
85. Reich, L. M., Bower, M., & Key, N. S. (2003). Role of the geneticist in testing and counseling for inherited thrombophilia. Genet Med, 5(3), 133-143.
86. Reid, W., & Perry, D. J. (2001). Internal jugular vein thrombosis following in vitro fertilization in a woman with protein S deficienty and heterozygosity for the prothrombin 3' UTR mutation, despite anticoagulation with heparin. Blood Coagulation and Fibrinolysis, 12, 487-489.
87. Rey, E., Kahn, S. R., David, M., & Shrier, I. (2003). Thrombophilic disorders and fetal loss: a meta-analysis. Lancet, 361(9361), 901-908.
88. Ridker, P. M., Goldhaber, S. Z., Danielson, E., Rosenberg, Y., Eby, C. S., Deitcher, S. R., Cushman, M., et al. (2003). Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med, 348(15), 1425-1434.
89. Ridker, P. M., Miletich, J. P., Hennekens, C. H., & Buring, J. E. (1997). Ethnic distribution of factor V Leiden in 4047 men and women. Implications for venous thromboembolism screening. Jama, 277(16), 1305-1307.
90. Ridker, P. M., Miletich, J. P., Stampfer, M. J., Goldhaber, S. Z., Lindpaintner, K., & Hennekens, C. H. (1995). Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation, 92(10), 2800-2802.
91. Robertson, L., Wu, O., Langhorne, P., Twaddle, S., Clark, P., Lowe, D. O., et al. (2006). Thrombophilia in pregnancy: a systematic review. Br J Haematol, 132, 171-196.
92. Rosendaal, F. R. (1999). Venous thrombosis: prevalence and interaction of risk factors. Haemostasis, 29(Suppl S1), 1-9.
93. Rosendaal, F. R. (2005). Venous thrombosis: the role of genes, environment, and behavior. Hematology (Am Soc Hematol Educ Program), 1-12.
94. Salomon, O., Steinberg, D. M., Zivelin, A., Gitel, S., Dardik, R., Rosenberg, N., et al. (1999). Single and combined prothrombotic factors in patients with idiopathic venous thromboembolism: prevalence and risk assessment. Arterioscler Thromb Vasc Biol, 19(3), 511-518.
95. Samama, M. M., Dahl, O. E., Quinlan, D. J., Mismetti, P., & Rosencher, N. (2003). Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica, 88(12), 1410-1421.
96. Saukko, P. M., Richards, S., Shepherd, M. H., Campbell, J. (2006). Are genetic tests exceptional? Lessons from a qualitative study on thrombophilia. Social Science & Medicine (in press).
97. Schambeck, C. M., Schwender, S., Haubitz, I., Geisen, U. E., Grossmann, R. E., & Keller, F. (1997). Selective screening for the Factor V Leiden mutation: is it advisable prior to the prescription of oral contraceptives? Thromb Haemost, 78(6), 1480-1483.
98. Seligsohn, U., & Lubetsky, A. (2001). Genetic susceptibility to venous thrombosis. N Engl J Med, 344(16), 1222-1231.
99. Seligsohn, U., & Zivelin, A. (1997). Thrombophilia as a multigenic disorder. Thromb Haemost, 78(1), 297-301.
100. Simioni, P., Prandoni, P., Burlina, A., Tormene, D., Sardella, C., Ferrari, et al. (1996). Hyperhomocysteinemia and deep-vein thrombosis. A case-control study. Thromb Haemost, 76(6), 883-886.
101. Simioni, P., Prandoni, P., Lensing, A. W., Scudeller, A., Sardella, C., Prins, M. H., et al. (1997). The risk of recurrent venous thromboembolism in patients with an Arg506->Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med, 336(6), 399-403.
102. Spector, E. B., Grody, W. W., Matteson, C. J., Palomaki, G. E., Bellissimo, D. B., Wolff, D. J., et al. (2005). Technical standards and guidelines: venous thromboembolism (Factor V Leiden and prothrombin 20210G >A testing): a disease-specific supplement to the standards and guidelines for clinical genetics laboratories. Genet Med, 7(6), 444-453.
103. Stark, J. E., & Kilzer, W. J. (2004). Venous thromboembolic prophylaxis in hospitalized medical patients. Ann Pharmacother, 38(1), 36-40.
104. Tait, R. C., Walker, I. D., Davidson, J. F., Islam, S. I., & Mitchell, R. (1990). Antithrombin III activity in healthy blood donors: age and sex related changes and prevalence of asymptomatic deficiency. Br J Haematol, 75(1), 141-142.
105. Tait, R. C., Walker, I. D., Reitsma, P. H., Islam, S. I., McCall, F., Poort, et al. (1995). Prevalence of protein C deficiency in the healthy population. Thromb Haemost, 73(1), 87-93.
106. Tal, J., Schliamser, L. M., Leibovitz, Z., Ohel, G., & Attias, D. (1999). A possible role for activated protein C resistance in patients with first and second trimester pregnancy failure. Hum Reprod, 14(6), 1624-1627.
107. Toole J. F., Malinow, M. R., Chambless, L. E., Spense, J. D., Pettigrew L. C., Howard, V. J., et al. (2004). Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA, (291), 565-575.
108. van Korlaar, I. M., Vossen, C. Y., Rosendaal, F. R., Bovill, E. G., Cushman, M., Naud, S., et al. (2004). The impact of venous thrombosis on quality of life. Thromb Res, 114(1), 11-18.
109. van Korlaar, I. M., Vossen, C. Y., Rosendaal, F. R., Bovill, E. G., Naud, S., Cameron, L. D., et al. (2005). Attitudes toward genetic testing for thrombophilia in asymptomatic members of a large family with inherited protein C deficiency. J Thromb Haemost, 3(11), 2437-2444.
110. Vandenbroucke, J. P., Koster, T., Briet, E., Reitsma, P. H., Bertina, R. M., & Rosendaal, F. R. (1994). Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet, 344(8935), 1453-1457.
111. Varga, E., Sturm, A., Misita, C., & Moll, S. (2004). Homocysteine and MTHFR mutations: relation to thrombosis and coronary artery disease. Circulation, 111, e289-e293.
112. Wu, O., Robertson, L., Twaddle, S., Lowe, G., Clark, P., Walker, I., et al. (2005). Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol, 131(1), 80-90.
113. Wu, O., Robertson, L., Twaddle, S., Lowe, G. D. O., Clark, P., Greaves, M., et al. (2006). Screening for thrombophilia in high-risk situations: Systemic review and cost-effectiveness analysis. The thrombosis risk and economic assessment of thrombophilia screening (TREATS) study. Health Technol Assess, 10(11), 1-110.
114. Younis, J. S. (2000). Thrombophilia and recurrent fetal loss-related? Fertil Steril, 73(3), 652-654.
115. Zoller, B., Berntsdotter, A., Garcia de Frutos, P., & Dahlback, B. (1995). Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood, 85(12), 3518-3523.
116. Zuber, M., Toulon, P., Marnet, L., & Mas, J. L. (1996). Factor V Leiden mutation in cerebral venous thrombosis. Stroke, 27(10), 1721-1723.